Worth reading
83Important
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
2096
¥ million (year-on-year change in ordinary profit)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentation materialsSecond quarter of the fiscal year ending March 202711 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥40,892 million+12.3%
Ordinary income¥4,194 million+99.9%
Net income¥2,920 million+104.3%
Selling, general and administrative expenses¥10,333 million
Full-year earnings forecast
Ordinary revenue
¥81,000 million
Ordinary income
¥5,000 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Revenue from animal hospital operations
41 %
BasisFull-year sales forecast: ¥3,800 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Ordinary profit achieved the first-half planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Earned premiums2,233
Incurred claims-2,090
Agency commissions-226
Catastrophe loss reserves105
Investment income1,908
Investment Expenses-381
Other Ordinary Income643
Other ordinary expenses-80
Selling, general and administrative expenses-15
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Premium revision level
6.3 %
FY ending March 2028 E/I loss ratio improvement outlook
Approximately 1.0–1.5
FY ending March 2029 E/I loss ratio improvement outlook
Approximately 3.0–3.5
Full-year revenue outlook for animal hospital operations
¥3,800 million
New initiatives
- Premium revisions from insurance contracts commencing in April 2027
- Expansion of white-label initiatives with domestic life and non-life insurers
- Stabilisation of asset management through the replacement of low-yield assets and assets with unrealised losses
- Expansion of the veterinary hospital operations business centred on JARVIS Animal Medical Center Tokyo
Key KPIsA metric the company considers important as a management benchmark.
Number of contracts held
1,433,091 contracts+6.4%
New contracts
121,342 contracts-12.4%
Continuation rate
88.5 %
Claims paid
2,588 thousand cases+6.1%
E/I loss ratio
65.1 %
Year-on-year change2.5
Expense ratio based on earned premiums
30.3 %
Year-on-year change-4.3
Combined ratio
95.4 %
Year-on-year change-1.8
どうぶつ健活 applications
124,232 contracts-1.9%
Veterinary hospitals served
7,068 Hospitals+0.9%
Segment results
Matching Services Business
Net Sales
¥1,130 million
Net sales in the same period of the previous year
¥1,158 million
Ordinary income
¥51 million
Ordinary profit for the prior-year quarter
¥104 million
Health innovation business
Net Sales
¥374 million
Net sales in the same period of the previous year
¥260 million
Ordinary income
¥-143 million
Ordinary profit for the prior-year quarter
¥-148 million
Veterinary hospital operations
Net Sales
¥1,554 million
Net sales in the same period of the previous year
¥1,221 million
Ordinary income
¥-551 million
Ordinary profit for the prior-year quarter
¥-108 million
Medium-term management plan targets
Aim for the optimal balance among growth investment, strengthening the business foundation and shareholder returnsFinancial targets
Consolidated solvency margin ratio
217.7 %
As ofEnd of the fiscal year ended March 2026
Number of employees
Inventors
165 People
Acquisition of treasury shares
Maximum acquisition amount
¥10 100 million
Acquisition period1 June 2026–31 July 2026
DesignationCompleted the repurchase of approximately ¥1 billion of shares
Three months of the current quarter
Number of new contracts acquired
61,000 contracts
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥40,892 million (YoY +12.3%) |
| Ordinary income | ¥4,194 million (YoY +99.9%) |
| Net income | ¥2,920 million (YoY +104.3%) |
| Selling, general and administrative expenses | ¥10,333 million |
| Three months of the current quarter | Number of new contracts acquired 61,000 contracts |
| Full-year earnings forecast | Ordinary revenue ¥81,000 million / Ordinary income ¥5,000 million |
| Progress against full-year forecast | Revenue from animal hospital operations 41 % |
| Self-assessment against the plan | Ordinary profit achieved the first-half plan |
| Segment results | Matching Services Business Net Sales ¥1,130 million / Net sales in the same period of the previous year ¥1,158 million / Ordinary income ¥51 million / Ordinary profit for the prior-year quarter ¥104 million / Health innovation business Net Sales ¥374 million / Net sales in the same period of the previous year ¥260 million / Ordinary income ¥-143 million / Ordinary profit for the prior-year quarter ¥-148 million / Veterinary hospital operations Net Sales ¥1,554 million / Net sales in the same period of the previous year ¥1,221 million / Ordinary income ¥-551 million / Ordinary profit for the prior-year quarter ¥-108 million |
| Breakdown of Factors Affecting the Change | Earned premiums 2,233 / Incurred claims -2,090 / Agency commissions -226 / Catastrophe loss reserves 105 / Investment income 1,908 / Investment Expenses -381 / Other Ordinary Income 643 / Other ordinary expenses -80 / Selling, general and administrative expenses -15 |
| Key KPIs | Number of contracts held 1,433,091 contracts (YoY +6.4%) / New contracts 121,342 contracts (YoY -12.4%) / Continuation rate 88.5 % / Claims paid 2,588 thousand cases (YoY +6.1%) / E/I loss ratio 65.1 % / Expense ratio based on earned premiums 30.3 % / Combined ratio 95.4 % / どうぶつ健活 applications 124,232 contracts (YoY -1.9%) / Veterinary hospitals served 7,068 Hospitals (YoY +0.9%) |
| Number of employees | Inventors 165 People |
| Assumptions Underlying the Business Outlook | Premium revision level 6.3 % / FY ending March 2028 E/I loss ratio improvement outlook Approximately 1.0–1.5 / FY ending March 2029 E/I loss ratio improvement outlook Approximately 3.0–3.5 / Full-year revenue outlook for animal hospital operations ¥3,800 million |
| Medium-term management plan targets | Aim for the optimal balance among growth investment, strengthening the business foundation and shareholder returns |
| Financial targets | Consolidated solvency margin ratio 217.7 % |
| Acquisition of treasury shares | Maximum acquisition amount ¥10 100 million / Acquisition period 1 June 2026–31 July 2026 / Designation Completed the repurchase of approximately ¥1 billion of shares |
| New initiatives | Premium revisions from insurance contracts commencing in April 2027, Expansion of white-label initiatives with domestic life and non-life insurers, Stabilisation of asset management through the replacement of low-yield assets and assets with unrealised losses, Expansion of the veterinary hospital operations business centred on JARVIS Animal Medical Center Tokyo |
Items this document does not state (12)
Operating profitGross Profit MarginOperating profit marginUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and profit increased due to steady new contract acquisitions, expansion of peripheral businesses, higher asset management income and the absence of costs associated with the transfer of AXA Direct contracts.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.